Stock THTX THERATECHNOLOGIES INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Theratechnologies Inc. Nasdaq

Equities

THTX

CA88338H7040

Market Closed - Nasdaq
Other stock markets
 02:00:00 18/07/2024 am IST 		5-day change 1st Jan Change
1.535 USD -2.69% Intraday chart for Theratechnologies Inc. +2.33% -5.25%
10/07 Theratechnologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2024 CI
10/07 Transcript : Theratechnologies Inc., Q2 2024 Earnings Call, Jul 10, 2024

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Theratechnologies: Fiscal Q2 Earnings Snapshot
AQ
Theratechnologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2024
CI
Transcript : Theratechnologies Inc., Q2 2024 Earnings Call, Jul 10, 2024
Theratechnologies Swings to Q2 Profit as Revenue Rises 25%; Confirms FY24 Guidance
MT
Theratechnologies Brief: Fiscal 2024 revenue guidance confirmed between US$87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 million
MT
Theratechnologies Brief: Positive net income of US$1 million realized with Adjusted EBITDA of $5.5 million For Q2
MT
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
AQ
Theratechnologies Brief: Q2 Revenue of US$22 million represents 25% growth year-over-year
MT
Theratechnologies Inc. Provides Earnings Guidance for the Year 2024
CI
North American Morning Briefing : Powell's Second Day of Remarks Awaited
DJ
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
AQ
Theratechnologies Up Near 5% In US After Hours On Data Related To Its Lead Investigational Peptide Drug Conjugate Candidate
MT
Theratechnologies Brief: Says Sudocetaxel Zendusortide ASCO 2024 Presentation "Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors"
MT
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
AQ
Theratechnologies Reports on its Annual Meeting of Shareholders
CI
Theratechnologies Reports on its Annual Meeting of Shareholders
AQ
Theratechnologies Inc. Announces Frank Holler as Chair of the Board of Directors
CI
Transcript : Theratechnologies Inc. - Shareholder/Analyst Call
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
AQ
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TH Stock
  4. THTX Stock
  5. News Theratechnologies Inc.